Mitochondrial DNA sequencing demonstrates clonality of peritoneal implants of borderline ovarian tumors.
Giulia GirolimettiPierandrea De IacoMartina ProcacciniRiccardo PanzacchiIvana KurelacLaura Benedetta AmatoGiulia DondiGiacomo CapraraClaudio CeccarelliDonatella SantiniAnna Maria PorcelliAnna Myriam PerroneGiuseppe GasparrePublished in: Molecular cancer (2017)
Borderline ovarian tumors are rare low malignant potential neoplasms characterized by the absence of stromal invasion, whose main prognostic factors are stage and type of peritoneal implants. The latter are defined as invasive when cell proliferation invades the underlying tissue (peritoneal surface, omentum and intestinal wall), or noninvasive. It is still unknown if these implants are metastatic spread from the primary ovarian mass or a neoplastic transformation de novo of the peritoneal surface. Mitochondrial DNA sequencing was performed to assess clonality in eight patients presenting both borderline ovarian tumors and implants. In 37.5% of the cases, the same mitochondrial DNA mutation was present in both borderline ovarian tumors and the peritoneal implant, being this evidence that implants may arise as a consequence of a spread from a single ovarian site.
Keyphrases
- mitochondrial dna
- copy number
- prognostic factors
- soft tissue
- cell proliferation
- end stage renal disease
- small cell lung cancer
- squamous cell carcinoma
- ejection fraction
- single cell
- chronic kidney disease
- newly diagnosed
- bone marrow
- gene expression
- genome wide
- risk assessment
- cell migration
- dna methylation
- patient reported
- human health